PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder
- The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms
- PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions
- Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions
The prevalence of autism spectrum disorder (“ASD”) in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (“CDC”). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the only treatment available on the market addresses symptoms of the condition rather than targeting the pathophysiology itself (https://nnw.fm/1ElYR ).
ASD is characterized by extreme versions of the processes governing the ability to focus attention and filter out sensory input. These processes often bring a wide range of special abilities, including the ability to hyperfocus on specific tasks, but they make normal everyday interactions and activities more challenging. These challenges don’t only affect those with ASD but the family and friends around them.
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs and bring hope to millions. The company’s CEO, Howard Weisman, recently shared insights into PaxMedica’s recent achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions. The full video can be found on the company’s website or through PaxMedica’s YouTube channel (https://nnw.fm/CGsDa ).
Mr. Weisman discussed the following key attributes during the video:
- A regulatory update with insights from the recent FDA Type-B meeting on October 25, 2023, shed light on the regulatory pathway for PAX-101 for HAT
- The financial boost of a successful $7 million public offering strengthened PaxMedica’s balance sheet and provided a financial platform for production and clinical trial initiatives
- The acquisition of suramin research assets from Rediscovery Life Sciences potentially expediting NDA submission for PAX-101
- A company update on clinical trial progress, with insights into future ASD trials
- Insight into PaxMedica’s business strategy to emphasize efficiency, production milestones, and key partnerships with organizations like Vox Nova
- The future vision of the company includes NDA plans for PAX-101 and potential advancements in autism treatment
The ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%. The growing prevalence of this disease globally, in addition to the rising awareness about ASD, including available options and treatments, are key factors driving the market (https://nnw.fm/BcAYu ). These estimates do not factor into the potential impact of treatments designed to address the core symptoms of ASD but provide insight into the market interest in therapeutics for ASD.
PaxMedica intends to continue into 2024 with the momentum it has gained with its achievements during the past year. The company is building a robust product pipeline to allow people with ASD to successfully integrate their behavior with others and improve their lives. Its lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting APT known for over 100 years.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms
- PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions
- Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions
The prevalence of autism spectrum disorder (“ASD”) in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (“CDC”). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the only treatment available on the market addresses symptoms of the condition rather than targeting the pathophysiology itself (https://nnw.fm/1ElYR ).
ASD is characterized by extreme versions of the processes governing the ability to focus attention and filter out sensory input. These processes often bring a wide range of special abilities, including the ability to hyperfocus on specific tasks, but they make normal everyday interactions and activities more challenging. These challenges don’t only affect those with ASD but the family and friends around them.
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms, is on a promising path to address the unmet medical needs and bring hope to millions. The company’s CEO, Howard Weisman, recently shared insights into PaxMedica’s recent achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions. The full video can be found on the company’s website or through PaxMedica’s YouTube channel (https://nnw.fm/CGsDa ).
Mr. Weisman discussed the following key attributes during the video:
- A regulatory update with insights from the recent FDA Type-B meeting on October 25, 2023, shed light on the regulatory pathway for PAX-101 for HAT
- The financial boost of a successful $7 million public offering strengthened PaxMedica’s balance sheet and provided a financial platform for production and clinical trial initiatives
- The acquisition of suramin research assets from Rediscovery Life Sciences potentially expediting NDA submission for PAX-101
- A company update on clinical trial progress, with insights into future ASD trials
- Insight into PaxMedica’s business strategy to emphasize efficiency, production milestones, and key partnerships with organizations like Vox Nova
- The future vision of the company includes NDA plans for PAX-101 and potential advancements in autism treatment
The ASD therapeutics market was valued at $1.93 billion in 2022 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9%. The growing prevalence of this disease globally, in addition to the rising awareness about ASD, including available options and treatments, are key factors driving the market (https://nnw.fm/BcAYu ). These estimates do not factor into the potential impact of treatments designed to address the core symptoms of ASD but provide insight into the market interest in therapeutics for ASD.
PaxMedica intends to continue into 2024 with the momentum it has gained with its achievements during the past year. The company is building a robust product pipeline to allow people with ASD to successfully integrate their behavior with others and improve their lives. Its lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting APT known for over 100 years.
For more information, visit the company’s website at www.PaxMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
